TENX
Tenax Therapeutics·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 3
Bearish signal 2
Stock Price Surged Significantly
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
RSI Overbought
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About TENX
Tenax Therapeutics, Inc.
A specialty pharmaceutical company that focused on products that address cardiovascular and pulmonary diseases
101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina 27517
--
Tenax Therapeutics, Inc., originally incorporated as a New Jersey corporation in 1967 under the name Rudmer, David & Associates, Inc., was subsequently renamed Synthetic Blood International, Inc. Effective June 30, 2008, the Company changed its registered seat to Delaware and changed its name to Oxygen Biotherapeutics, Inc. On September 19, 2014, the company changed its name to Tenax Therapeutics, Inc. The Company is a specialty pharmaceutical company focused on identifying, developing and commercializing products to address cardiovascular and pulmonary diseases with unmet medical needs. The company's primary business objective is to identify, develop and commercialize novel therapeutic products for disease indications in important areas representing clinical needs and business opportunities.
Company Financials
EPS
TENX has released its 2025 Q3 earnings. EPS was reported at -0.4, versus the expected -1.12, beating expectations. The chart below visualizes how TENX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
